Loading…
Loading…
Sentiment · FY2026 Q1
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Gena Wang | Barclays | 8 | 13% |
| Luca Issi | RBC Capital Markets | 6 | 17% |
| Courtney Breen | Bernstein | 5 | 20% |
| Salveen Richter | Goldman Sachs | 5 | 0% |
| Cory Kasimov | Evercore ISI | 5 | 20% |
| Mike Yee | UBS | 5 | 0% |
| Jessica Fye | JPMorgan | 4 | 25% |
| Terence Flynn | Morgan Stanley | 4 | 0% |
| Greg Wiessner | TD Cowen | 4 | 0% |
| Eliana Merle | UBS | 3 | 0% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Barclays | 2 | 10 | 10% |
| UBS | 2 | 8 | 0% |
| TD Cowen | 2 | 6 | 0% |
| RBC Capital Markets | 1 |
| 6 |
| 17% |
| Evercore ISI | 1 | 5 | 20% |
| Goldman Sachs | 1 | 5 | 0% |
| Bernstein | 1 | 5 | 20% |
| Morgan Stanley | 1 | 4 | 0% |
Moderna reported revenue of $235 million with COVID and RSV vaccines both at seasonal lows, while operating losses continued narrowing as cost reduction measures took full effect with total operating expenses declining 20% year-over-year. Management reiterated FY2026 revenue guidance of $3.5-4.5 billion and confirmed the multi-product commercial strategy, with the flu-COVID combination vaccine on track for regulatory submission and the CMV vaccine advancing toward a potential 2027 approval.
Innovation & R&D | Regulation Policy | Revenue Growth | Cost Pressure | Product Launch | Guidance Reliability | Demand | Competitive Dynamics | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 12 | 8 | 1 | 3 | 2 | 2 | ||
| 2025Q1 | 6 | 4 | 1 | 2 | 1 | 2 | 1 | |
| 2025Q2 | 5 | 2 | 1 | 1 | 1 | 1 | 1 | |
| 2025Q3 | 6 | 3 | 2 | 1 | 1 | 2 | 1 | |
| 2025Q4 | 3 | 3 | 1 | 1 | 1 | |||
| 2026Q1 | 9 | 1 | 3 | 1 | 2 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Innovation & R&D | 12 | 6 | 5 | 6 | 3 | 9 |
| Regulation Policy | 8 | 2 | 3 | 1 | ||
| Revenue Growth | 1 | 4 | 1 | 3 | 3 | |
| Cost Pressure | 3 | 1 | 1 | 2 | 1 | 1 |
| Product Launch | 2 | 2 | 1 | 1 | 2 | |
| Guidance Reliability | 2 | 1 | 1 | 1 | ||
| Demand | 2 | 1 | 2 | |||
| Competitive Dynamics | 1 | 1 | 1 | 1 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
MRNA Moderna | 8 | +263.6% | |
| ALNY Alnylam Pharmaceuticals | 9 | +96.4% | |
| INCY Incyte | 9 | +20.9% | |
| INSM Insmed Incorporated | 8 | +229.6% | |
| REGN Regeneron Pharmaceuticals | 7 | +19.0% | |
| TECH Bio-Techne | 4 | -1.5% | |
| VRTX Vertex Pharmaceuticals | 6 | +7.8% |